The Health Business Blog is taking a break this week, and re-running some posts from August 2008. If you’d like to comment, please do so on the original post.
Rule 5: They pay for a plan.
What do people pay for when they come to the medical office? They pay for opinion, yes. They pay for knowledge as well. But what they really pay for is a plan of action….They want to know what is going to be done to help. I try and give a plan, either verbal or written, to each patient that walks out of the exam room. What medications are given and why? What medications are to be stopped? What tests are ordered and what will the results mean? When is the next appointment? What should they call for if they have problems? The better I can answer these questions, the more confidently the patient will walk out of the exam room. The days of paternalistic medicine are over – no handing a prescription and just saying “take it.” Patients should know why they are putting things in their body.
I asked SimulConsult CEO Michael Segal, MD, PhD for his thoughts on this one:
This is why many doctors give treatment plans that are worthless or worse – patients expect something more than advice that the problem will get better by itself. Much use of band-aids (with potential latex allergies), antibiotics (with potential bacterial resistance) and cold medicines (with side effects such as secondary infections) is attributable to doctors following Parker-Pope’s rule when they should be providing reassurance. In addition, this focus on intervention is built into reimbursement schedules, making it so doctors are paid little for diagnosis and paid well for intervention.
Then this morning I saw this piece this morning from MedPage Today (For Unexplained Infertility, Continued Trying Is as Good as Treatment)
ABERDEEN, Scotland, Aug. 8 — Commonly used treatments for unexplained infertility may be ineffective in raising the odds of pregnancy, researchers found.
The live birth rate was similar whether couples continued to try for pregnancy naturally, used oral clomiphene (Serophene, Clomid), or had unstimulated intrauterine insemination (17% versus 14% and 23%), reported Siladitya Bhattacharya, M.D., of the University of Aberdeen, and colleagues online in the BMJ.
However, women in the randomized trial were least satisfied with the just-keep-trying approach — dubbed expectant management by the researchers — despite a significant difference in outcomes.